KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)
$79.38 0.35 (0.4429%)
Analysed KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) News Sources
Kiniksa Pharmaceuticals to Present at Canaccord Genuity 46th Annual Growth Conference
07-08-2026
yahoo.com
Kiniksa's Sales Are Expected To Decline — Why That's All According To Plan
21-08-2026
yahoo.com
TGTX Stock Outperforms 95% of Stocks. Here's Why.
24-08-2026
yahoo.com
Three Biotech Stocks Stick Out With Their Stellar Charts
21-08-2026
yahoo.com
Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution
28-07-2026
yahoo.com
Kiniksa Pharmaceuticals International Q2 Earnings Call Highlights
28-07-2026
marketbeat.com
Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales Guidance
28-07-2026
advfn.com
Why Kiniksa Pharmaceuticals (KNSA) Is Up 29.6% After Raising 2026 Revenue Guidance And Advancing Pipeline
29-07-2026
yahoo.com
Could Kiniksa Pharmaceuticals International (KNSA) Be 16% Overvalued After Raised 2026 Guidance?
30-07-2026
yahoo.com
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
15-08-2026
marketbeat.com
What is the current price of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)?
The current price of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) is $79.38.
KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) absolute price change since previous trading day?
The absolute price change of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) since the previous trading day is $0.35.
KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) percentage price change since previous trading day?
The percentage price change of KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) since the previous trading day is 0.4429%.
What is the most recent average sentiment score for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)?
The most recent average sentiment score for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) is 81 out of 100.
What is the most recent average sentiment for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)?
The most recent sentiment for KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ) is .
SEC-8K** Filing Available For KINIKSA PHARMACEUTICALS INTE (KNSA:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.